Maxim Group Reiterates “Hold” Rating for Theriva Biologics (NYSEAMERICAN:TOVX)

Theriva Biologics (NYSEAMERICAN:TOVX)‘s stock had its “hold” rating reaffirmed by stock analysts at Maxim Group in a research report issued on Thursday, Marketbeat Ratings reports.

Theriva Biologics Stock Performance

Shares of TOVX stock opened at $0.53 on Thursday. Theriva Biologics has a fifty-two week low of $0.47 and a fifty-two week high of $10.75. The firm has a market capitalization of $1.47 million, a P/E ratio of -0.02 and a beta of 1.22. The stock’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.62.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.